Loading data for STVN — first visit, this takes a few seconds.

Alert

Stevanato Group S.p.A. (STVN)

NYSE: STVN · Real-Time Price · USD

22.38

-0.32 (-1.41%)

At close: Aug 26, 2026, 8:00 PM

The price, the headline numbers and the latest news, in one place.

-1.41% (1D)

No data available

Bid	n/a
Market Cap	6.11B
Revenue (ttm)	1.23B
Net Income (ttm)	134.61M
	0.74
	0.56
	39.96
	26.63
P/B (ttm)	3.41
P/S (ttm)	4.99
Earnings Date	Nov 5, 2026

Ask	22.9
Volume	499,243
Avg. Volume (20D)	392,815
Open	22.56
Previous Close	22.70
Day's Range	22.25 - 23.00
52-Week Range	12.89 - 28.00
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and am...

[Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

IPO Date Jul 16, 2021

Employees 6,010

Stock Exchange NYSE

Ticker Symbol STVN

Website https://www.stevanatogroup.com

Full Company Profile

Financial Performance

In 2025, Stevanato S.p.A.'s revenue was 1.19B, an increase of 7.45% compared to the previous year's 1.1B. Earnings were 139.84M, an increase of 18.73%.

Financial Statements

Earnings Surprise

Stevanato S.p.A. has released their quarterly earnings on Aug 4, 2026:

Revenue of $302M misses estimates by $0, with 7.84% YoY growth.
EPS of 0.16 exceeds estimates by 0.01, with 23.08% YoY growth.

Next Earnings Release

Stevanato Group S.p.A. is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

2 weeks ago · Simply Wall St.

Stevanato Group (STVN) Could Be 16% Undervalued Following Earnings And Guidance Update

What Stevanato Group’s latest earnings and guidance mean for investors Stevanato Group (STVN) has been in focus after its early August 2026 earnings report, which combined higher sales with lower net ...

2 weeks ago · Simply Wall St.

How Investors Are Reacting To Stevanato Group (STVN) Trimmed Guidance And New GLP-1 Pen Approvals

Stevanato Group S.p.A. recently reported past second-quarter 2026 results showing sales of €302 million with lower net income, slightly trimmed its full-year revenue guidance to €1.26–€1.28 billion, a...

2 weeks ago · Simply Wall St.

Stevanato Group (STVN) Stock Looks Cheap On Cash Flow But Pricey On Earnings

Stevanato Group stock has declined 34.6% over the past three years, and current checks send mixed valuation signals, with an intrinsic value estimate suggesting the shares trade at a discount while ma...

2 weeks ago · MarketBeat

Stevanato Group Q2 Earnings Call Highlights

Stevanato Group (NYSE:STVN) reported second-quarter 2026 revenue growth of 8% as demand for higher-value drug containment and delivery products helped lift profitability, while the company updated its...

3 weeks ago · Zacks

Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"

Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Page 1 of 2

Stevanato Group S.p.A. (STVN)